ARRAY-520-216; A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma.
Description
This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma.
Details
| Condition | multiple myeloma |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX4230 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.